NCT07200154View on ClinicalTrials.gov

Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 30, 2028

Study Completion Date

September 30, 2028

Conditions
Limited-stage Small-cell Lung CancerConcurrent Chemoradiation Therapy
Interventions
DRUG

Adebrelimab with concurrent chemoradiotherapy

Adebrelimab combined with chemotherapy and concurrent radiotherapy, followed by maintenance therapy with Adebrelimab until disease progression or intolerable toxicity, for up to 2 years.

Trial Locations (1)

100142

Peking University Cancer Hospital and Institute, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER